AI Generated Image
Engineered probiotic bacteria boost immune attack against pancreatic cancer
News-Medical • • technology
Key Points:
- Researchers at the University of Chicago developed BifidoSumIL-2, an engineered probiotic bacterium Bifidobacterium longum, to deliver a modified immune-stimulating molecule directly inside pancreatic tumors, overcoming the tumor's immune-suppressive environment.
- BifidoSumIL-2 releases SumIL-2, an engineered form of interleukin-2 that selectively activates cancer-fighting T cells while minimizing activation of regulatory T cells, enhancing immune response specifically within tumors.
- The anaerobic nature of Bifidobacterium allows it to thrive in low-oxygen tumor environments but not in healthy oxygen-rich tissues, enabling targeted delivery and reducing systemic side effects.
- In animal models, BifidoSumIL-2 suppressed pancreatic tumor growth and improved outcomes when combined with chemotherapy, radiotherapy, or immunotherapy, suggesting strong potential for combination cancer treatments.
- While promising, BifidoSumIL-2 requires further testing in humans to assess long-term safety, delivery methods, and efficacy, representing a novel "bugs as drugs" approach to treating hard-to-treat cancers like pancreatic cancer.
